PET Agent Receives FDA Fast Track Designation for mCRPC
The PET radiopharmaceutical SAR-bisPSMA has garnered three FDA fast track designations in a six-month period for use in the detection and management of prostate cancer.
The Food and Drug Administration (FDA) has granted a fast track designation for the positron emission tomography (PET) agent 67Cu-SAR-bisPSMA for the treatment of adults with metastatic castration-resistant prostate cancer (mCRPC) previously treated with androgen receptor pathway inhibitors (ARPIs).
Clarity Pharmaceuticals, the developer of 67Cu-SAR-bisPSMA, noted the fast track designation was based on preliminary data from the ongoing phase I/IIa SECuRE study of the PET agent.
In a cohort of patients with high baseline prostate-specific antigen (PSA) levels (median of 112.86 ng/mL), 77 percent of whom had bone metastasis, the use of 67Cu-SAR-bisPSMA resulted in PSA reductions for 73 percent of patients, according to Clarity Pharmaceuticals.
In preliminary data from the ongoing phase I/IIa SECuRE study, the PET agent 67Cu-SAR-bisPSMA reportedly achieved PSA level reductions in 73 percent of patients with metastatic castration-resistant prostate cancer (mCRPC), 77 percent of whom had bone metastasis, according to Clarity Pharmaceuticals, the developer of the PET agent. (Image courtesy of Adobe Stock.)
Noting that 59 percent of the cohort had received three or more previous lines of therapy, the company said 45 percent of the SECuRE trial participants have had greater than 50 percent reductions in PSA levels.
(Editor’s note: For related content on prostate cancer imaging, click here.)
Clarity Pharmaceuticals said the current FDA fast track designation follows two prior fast track designations for the diagnostic version of the SAR-bisPSMA radiopharmaceutical (64Cu-SAR-bisPSMA).
“Receiving 3 FTDs for the one molecule, SAR-bisPSMA, within the last six months is an incredible achievement for Clarity, highlighting how impressive our science and development are, the significance of the diagnostic and therapeutic data so far, and the high unmet need for better therapies and diagnostics in prostate cancer,” noted Alan Taylor, Ph.D., the executive chairperson for Clarity Pharmaceuticals.
Study: AI-Generated ADC Maps from MRI More Than Double Specificity in Prostate Cancer Detection
June 5th 2025Emerging research showed that AI-generated ADC mapping from MRI led to significant increases in accuracy, PPV and specificity in comparison to conventional ADC mapping while achieving a 93 percent sensitivity for PCa.
The Reading Room Podcast: Current Perspectives on the Updated Appropriate Use Criteria for Brain PET
March 18th 2025In a new podcast, Satoshi Minoshima, M.D., Ph.D., and James Williams, Ph.D., share their insights on the recently updated appropriate use criteria for amyloid PET and tau PET in patients with mild cognitive impairment.
ASCO: Study Reveals Significant Racial/Ethnic Disparities with PSMA PET Use for Patients with mPCa
May 30th 2025Latinx patients with metastatic prostate cancer were 63 percent less likely than non-Hispanic White patients to have PSMA PET scans, according to a study of 550 patients presented at the American Society of Clinical Oncology (ASCO) conference.
What a New PSMA PET/CT Study Reveals About Local PCa Treatment and High-Risk Recurrence
May 16th 2025For patients at high-risk for biochemical recurrence of prostate cancer, PSMA PET/CT findings revealed that 77 percent had one or more prostate lesions after undergoing local radiation therapy or radical prostatectomy, according to a recent study.
Study Shows No Impact of Hormone Therapy on PET/CT with 18F-Piflufolastat in PCa Imaging
May 7th 2025For patients with recurrent or metastatic prostate cancer, new research findings showed no significant difference in the sensitivity of 18F-piflufolastat PET/CT between patients on concurrent hormone therapy and those without hormone therapy.
